<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791076</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00010957</org_study_id>
    <nct_id>NCT00791076</nct_id>
  </id_info>
  <brief_title>The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 &amp; Post-pancreatectomy Diabetic Patients</brief_title>
  <official_title>The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 (Auto-immune) and Post-pancreatectomy Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to see if pancreatic polypeptide (PP), a hormone that is
      naturally produced by the pancreas and that works to control the amount of glucose that the
      liver makes, will reduce the amount of insulin required for people who must take insulin to
      maintain their normal blood glucose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pancreas is a large gland located behind the stomach. One of the functions of the
      pancreas is to produce two hormones: insulin and pancreatic polypeptide. Insulin helps the
      cells to take in glucose. The liver makes glucose and insulin normally acts to decrease or
      shut off the liver's production of glucose. However, in patients whose pancreas no longer
      makes insulin or makes low levels of pancreatic polypeptide the liver cannot perform these
      duties as well. Studies have shown that these important functions of the liver are improved
      for these patients when pancreatic polypeptide is given together with their insulin. Because
      PP increases the liver's sensitivity to insulin and thereby reduces the amount of glucose
      produced by the liver, this will result in fewer swings in blood sugar levels both in the
      upper and lower range. With fewer swings in blood glucose, a patient should decrease the
      amount of insulin used. One of the main benefits of lowering total insulin requirement is a
      reduction in the development of dangerous low blood sugar levels.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left JHU
  </why_stopped>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Amount of Insulin Administered While on Placebo/PP.</measure>
    <time_frame>2 years</time_frame>
    <description>Glucose values and the pattern of glycemic excursions over the 72 hour test period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Hypoglycemia Defined as &lt; 60 mg/dl.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic Polypeptide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic Polypeptide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2pmol/kg-1/min-1 placebo infused continuously over 72 hours.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pancreatic Polypeptide (PP)</intervention_name>
    <description>2pmol/kg-1/min-1 PP infused continuously over 72 hours.</description>
    <arm_group_label>Pancreatic Polypeptide</arm_group_label>
    <other_name>PP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers between the ages of 18-75 with:

          -  10 subjects who are status post pancreatic resection and 10 volunteers who are Type 1
             diabetic for &gt; 8 years (volunteers must have a stable glycemic profile that includes
             use of an insulin pump to control their blood glucose) with or without prior
             pancreatic resection.

          -  HbA1c levels ≤ 8.5.

        Exclusion Criteria:

          -  Lactating or pregnant females.

          -  Brittle or Labile diabetics: Volunteers with extremely erratic patterns of glucose
             control with large fluctuations in glucose levels for no obvious reason.

          -  Allergy to beef or beef by-products.

          -  Hypoglycemia within the past year requiring medical or other assistance to correct.

          -  Known autonomic neuropathy.

          -  Documented blood glucose under 60 mg within the past year and hypoglycemic
             unawareness.

          -  Durations of type 1 Diabetes Melitis (DM) ≤ 8 years.

          -  Not currently on pump therapy.

          -  Type 1 DM who has a BMI ≥ 35.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Elahi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2017</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin pump therapy</keyword>
  <keyword>Type 1 diabetic</keyword>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Pancreatic resection</keyword>
  <keyword>Pancreatic polypeptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pancreatic Polypeptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Saline
Placebo: 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.
OR
Pancreatic Polypeptide
Pancreatic Polypeptide (PP): 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was terminated,PI left institution</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This study was terminated prematurely when the PI left the institution. Although 8 participants were enrolled in this study, their assignment to Arm/Group is unknown, since no data are available.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>2pmol/kg-1/min-1 saline infused continuously over 72 hours OR
2pmol/kg-1/min-1 PP infused continuously over 72 hours.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=18 and &lt;=75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Insulin Administered While on Placebo/PP.</title>
        <description>Glucose values and the pattern of glycemic excursions over the 72 hour test period.</description>
        <time_frame>2 years</time_frame>
        <population>Data was not collected for this outcome measure. The P.I. left the institution and the study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Saline
Placebo: 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
          </group>
          <group group_id="O2">
            <title>Pancreatic Polypeptide</title>
            <description>Pancreatic Polypeptide
Pancreatic Polypeptide (PP): 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Insulin Administered While on Placebo/PP.</title>
          <description>Glucose values and the pattern of glycemic excursions over the 72 hour test period.</description>
          <population>Data was not collected for this outcome measure. The P.I. left the institution and the study was terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Hypoglycemia Defined as &lt; 60 mg/dl.</title>
        <time_frame>72 hours</time_frame>
        <population>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Data, if collected,is unknown since no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Saline
Placebo: 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
          </group>
          <group group_id="O2">
            <title>Pancreatic Polypeptide</title>
            <description>Pancreatic Polypeptide
Pancreatic Polypeptide (PP): 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Hypoglycemia Defined as &lt; 60 mg/dl.</title>
          <population>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Data, if collected,is unknown since no data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Time frame for Adverse event data, if collected, is unknown since no data are available.</time_frame>
      <desc>The PI left the institution and this study was terminated due to noncompliance with our Institutional Review Board. Adverse event data, if collected, is unknown since no data are available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Saline Placebo</title>
          <description>Saline
Placebo: 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
        </group>
        <group group_id="E2">
          <title>Pancreatic Polypeptide</title>
          <description>Pancreatic Polypeptide
Pancreatic Polypeptide (PP): 2pmol/kg-1/min-1 PP or placebo infused continuously over 72 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johns Hopkins University Clinical Trials Program</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-6484</phone>
      <email>registerclinicaltrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

